Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil

BACKGROUND: Chronic hepatitis C affects approximately 170 million people worldwide, and thus being one of the main causes of chronic liver disease. About 20% of patients with chronic hepatitis C will develop cirrhosis over 20 years, and present an increased risk of developing hepatic complications....

Descripción completa

Detalles Bibliográficos
Autores principales: Barros, Fabio MR, Cheinquer, Hugo, Tsuchiya, Carolina T, Santos, Eduardo AV
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851805/
https://www.ncbi.nlm.nih.gov/pubmed/24103591
http://dx.doi.org/10.1186/1478-7547-11-25

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851805/
https://www.ncbi.nlm.nih.gov/pubmed/24103591
http://dx.doi.org/10.1186/1478-7547-11-25

Ejemplares similares